Drug intelligence / Profile preview

bivalent oral polio vaccine

Development stage: Unknown
Lead developer: Bilthoven Biologicals
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

bOPV is a live-attenuated, bivalent oral polio vaccine containing Sabin strains of poliovirus types 1 and 3. It is used for active immunization against poliomyelitis caused by these two serotypes. Following the global withdrawal of trivalent oral polio vaccine (tOPV) in 2016 due to the eradication of wild poliovirus type 2, bOPV became the primary tool in routine immunization and outbreak response in many countries. The vaccine works by inducing intestinal immunity, which prevents the shedding and transmission of the virus, as well as systemic immunity. Bilthoven Biologicals (a subsidiary of the Serum Institute of India) is a key developer and manufacturer of this vaccine.

Other names: bOPVBivalent Oral Polio Vaccine (Sabin Types 1 and 3)

Beyond the preview

Go deeper on bivalent oral polio vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bivalent oral polio vaccine.

Explore the full profile